(TARA) Protara Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74365U1079

TARA-002, Intravenous Choline Chloride

Stock: Biotechnology
Age 11.3y
MCap 332m
Avg Vol 1.08M (5.82M USD)
Beta 1.136
Volatility 99.58%

EPS (Earnings per Share)

EPS (Earnings per Share) of TARA over the last years for every Quarter: "2020-12": -0.44, "2021-03": -1.2, "2021-06": -1.14, "2021-09": -0.96, "2021-12": -0.91, "2022-03": -0.96, "2022-06": -0.8, "2022-09": -0.68, "2022-12": -1.55, "2023-03": -0.8, "2023-06": -1, "2023-09": -0.87, "2023-12": -0.9, "2024-03": -0.97, "2024-06": -0.45, "2024-09": -0.5024, "2024-12": -0.43, "2025-03": -0.29, "2025-06": -0.35, "2025-09": -0.31,
EPS CAGR: 17.54%
EPS Trend: 74.7%
Last SUE: 0.54
Qual. Beats: 0

Revenue

Revenue of TARA over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 1.208, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0.332, 2025-03: 0, 2025-06: 0, 2025-09: 0,
Rev. CAGR: 0.00%
Rev. Trend: 10.5%
Last SUE: 0.00
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 99.6%
Value at Risk 5%th 134%
Relative Tail Risk -17.99%
Reward TTM
Sharpe Ratio 0.96
Alpha 43.16
CAGR/Max DD 0.43
Character TTM
Hurst Exponent 0.594
Beta 1.136
Beta Downside 1.110
Drawdowns 3y
Max DD 71.23%
Mean DD 38.46%
Median DD 40.10%

Description: TARA Protara Therapeutics January 19, 2026

Protara Therapeutics, Inc. (NASDAQ: TARA) is a New York-based clinical-stage biopharma focused on developing transformative cell-based and metabolic therapies for oncology and rare diseases.

The company’s lead asset, TARA-002, is a genetically engineered cell therapy currently enrolling a Phase II trial for non-muscle invasive bladder cancer (NMIBC) and a separate Phase II study for lymphatic malformations, positioning it in two high-unmet-need indications.

Protara is also advancing an intravenous choline chloride formulation intended to replace phospholipid substrates in patients receiving parenteral nutrition, a niche market estimated at > $200 million annually in the United States.

Key financial and sector metrics to watch: (1) as of the latest 10-Q, cash and cash equivalents stood at roughly $45 million, giving the firm an estimated 12-month runway at current burn rates; (2) R&D spend has risen ~30 % YoY, reflecting the Phase II escalation; and (3) the broader biotech financing environment remains supportive, with Q4 2023 venture capital inflows into cell-therapy firms up 18 % year-over-year, which could ease future fundraising.

For a deeper, data-driven view of TARA’s valuation sensitivities and cash runway, ValueRay’s analytics platform provides a granular breakdown worth exploring.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income: -52.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.34 > 0.02 and ΔFCF/TA 3.74 > 1.0
NWC/Revenue: 37.9k% < 20% (prev 6328 %; Δ 31.5k% < -1%)
CFO/TA -0.34 > 3% & CFO -48.7m > Net Income -52.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 13.69 > 1.5 & < 3
Outstanding Shares: last quarter (42.3m) vs 12m ago 89.31% < -2%
Gross Margin: 18.98% > 18% (prev 0.70%; Δ 1827 % > 0.5%)
Asset Turnover: 0.28% > 50% (prev 1.28%; Δ -1.01% > 0%)
Interest Coverage Ratio: -11.69 > 6 (EBITDA TTM -56.4m / Interest Expense TTM 4.86m)

Altman Z'' -15.00

A: 0.87 (Total Current Assets 135.6m - Total Current Liabilities 9.91m) / Total Assets 144.6m
B: -1.97 (Retained Earnings -285.1m / Total Assets 144.6m)
C: -0.48 (EBIT TTM -56.8m / Avg Total Assets 119.4m)
D: -23.08 (Book Value of Equity -284.9m / Total Liabilities 12.3m)
Altman-Z'' Score: -28.15 = D

Beneish M 1.00

DSRI: 15.05 (Receivables 1.00m/242.0k, Revenue 332.0k/1.21m)
GMI: 3.71 (GM 18.98% / 70.45%)
AQI: 0.91 (AQ_t 0.03 / AQ_t-1 0.04)
SGI: 0.27 (Revenue 332.0k / 1.21m)
TATA: -0.03 (NI -52.9m - CFO -48.7m) / TA 144.6m)
Beneish M-Score: 10.39 (Cap -4..+1) = D

ValueRay F-Score (Strict, 0-100) 33.03

1. Piotroski: 1.0pt
2. FCF Yield: -24.07%
3. FCF Margin: data missing
4. Debt/Equity: 0.03
5. Debt/Ebitda: data missing
6. ROIC - WACC: -40.13%
7. RoE: -35.13%
8. Revenue Trend: 10.54%
9. EPS Trend: 74.75%

What is the price of TARA shares?

As of January 28, 2026, the stock is trading at USD 7.27 with a total of 1,838,584 shares traded.
Over the past week, the price has changed by +29.82%, over one month by +35.63%, over three months by +41.99% and over the past year by +63.37%.

Is TARA a buy, sell or hold?

Protara Therapeutics has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy TARA.
  • Strong Buy: 5
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the TARA price?

Issuer Target Up/Down from current
Wallstreet Target Price 25.5 250.8%
Analysts Target Price 25.5 250.8%
ValueRay Target Price 6.9 -5%

TARA Fundamental Data Overview January 27, 2026

P/B = 2.5074
Revenue TTM = 332.0k USD
EBIT TTM = -56.8m USD
EBITDA TTM = -56.4m USD
Long Term Debt = 3.66m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.22m USD (from shortTermDebt, last quarter)
Debt = 3.66m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -8.89m USD (from netDebt column, last quarter)
Enterprise Value = 202.7m USD (331.7m + Debt 3.66m - CCE 132.7m)
Interest Coverage Ratio = -11.69 (Ebit TTM -56.8m / Interest Expense TTM 4.86m)
EV/FCF = -4.15x (Enterprise Value 202.7m / FCF TTM -48.8m)
FCF Yield = -24.07% (FCF TTM -48.8m / Enterprise Value 202.7m)
FCF Margin = -14.7k% (FCF TTM -48.8m / Revenue TTM 332.0k)
Net Margin = -15.9k% (Net Income TTM -52.9m / Revenue TTM 332.0k)
Gross Margin = 18.98% ((Revenue TTM 332.0k - Cost of Revenue TTM 269.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.40 (Enterprise Value 202.7m / Total Assets 144.6m)
Interest Expense / Debt = 41.08% (Interest Expense 1.50m / Debt 3.66m)
Taxrate = 21.0% (US default 21%)
NOPAT = -44.9m (EBIT -56.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.69 (Total Current Assets 135.6m / Total Current Liabilities 9.91m)
Debt / Equity = 0.03 (Debt 3.66m / totalStockholderEquity, last quarter 132.3m)
Debt / EBITDA = 0.16 (negative EBITDA) (Net Debt -8.89m / EBITDA -56.4m)
Debt / FCF = 0.18 (negative FCF - burning cash) (Net Debt -8.89m / FCF TTM -48.8m)
Total Stockholder Equity = 150.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.32% (Net Income -52.9m / Total Assets 144.6m)
RoE = -35.13% (Net Income TTM -52.9m / Total Stockholder Equity 150.6m)
RoCE = -36.81% (EBIT -56.8m / Capital Employed (Equity 150.6m + L.T.Debt 3.66m))
RoIC = -29.79% (negative operating profit) (NOPAT -44.9m / Invested Capital 150.6m)
WACC = 10.34% (E(331.7m)/V(335.4m) * Re(10.10%) + D(3.66m)/V(335.4m) * Rd(41.08%) * (1-Tc(0.21)))
Discount Rate = 10.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 92.86%
Fair Price DCF = unknown (Cash Flow -48.8m)
EPS Correlation: 74.75 | EPS CAGR: 17.54% | SUE: 0.54 | # QB: 0
Revenue Correlation: 10.54 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.35 | Chg30d=+0.011 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=-1.46 | Chg30d=-0.014 | Revisions Net=-1 | Growth EPS=-9.8% | Growth Revenue=+0.0%

Additional Sources for TARA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle